Physician profile
Patrick Nowlin Bowman
NPI 1114557725
$841.99
in general payments reported to CMS, 2019-2025
16 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.67 · 2023: $57.04 · 2024: $204 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $117.43 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $114.15 | 2022-2025 | |
| Stryker Corporation | $101.20 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Biotech, INC. | $80.42 | 2024-2025 | Rybrevant |
| Tempus Ai, INC | $71.50 | 2025 | Xt Cdx |
| Sobi, INC | $62.04 | 2024 | |
| Glaxosmithkline, LLC. | $52.92 | 2025 | Blenrep, Ojjaara, Jemperli |
| Springworks Therapeutics, INC. | $41.10 | 2025 | Ogsiveo |
| Eisai INC. | $33.74 | 2025 | |
| Merck Sharp & Dohme LLC | $31.35 | 2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $28.28 | 2025 | Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $27.51 | 2025 | |
| Deciphera Pharmaceuticals INC. | $24.98 | 2025 | Romvimza, Qinlock |
| Day One Biopharmaceuticals | $23.40 | 2024 | Ojemda |
| Karyopharm Therapeutics INC. | $16.05 | 2025 | Xpovio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $15.92 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.